Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

Stephen E. Goldstone; Heiko Jessen; Joel M. Palefsky; Anna R. Giuliano; Edson D. Moreira; Eftyhia Vardas; Carlos Aranda; Richard J. Hillman; Daron G. Ferris; Francois Coutlee; J. Brooke Marshall; Scott Vuocolo; Richard M. Haupt; Dalya Guris; Elizabeth Garner

doi:10.1016/j.vaccine.2013.06.057

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

Stephen E. Goldstone, Heiko Jessen, Joel M. Palefsky, Anna R. Giuliano, Edson D. Moreira, Eftyhia Vardas, Carlos Aranda, Richard J. Hillman, Daron G. Ferris, Francois Coutlee, J. Brooke Marshall, Scott Vuocolo, Richard M. Haupt, Dalya Guris, Elizabeth Garner

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

Original language	English
Pages (from-to)	3849-3855
Number of pages	7
Journal	Vaccine
Volume	31
Issue number	37
DOIs	https://doi.org/10.1016/j.vaccine.2013.06.057
State	Published - 20 Aug 2013

Keywords

HPV
Males
Men who have sex with men
Young

Access to Document

10.1016/j.vaccine.2013.06.057

Cite this

Goldstone, S. E., Jessen, H., Palefsky, J. M., Giuliano, A. R., Moreira, E. D., Vardas, E., Aranda, C., Hillman, R. J., Ferris, D. G., Coutlee, F., Marshall, J. B., Vuocolo, S., Haupt, R. M., Guris, D., & Garner, E. (2013). Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine, 31(37), 3849-3855. https://doi.org/10.1016/j.vaccine.2013.06.057

@article{91eb935981fe420995331216777d7ec9,

title = "Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males",

abstract = "A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.",

keywords = "HPV, Males, Men who have sex with men, Young",

author = "Goldstone, {Stephen E.} and Heiko Jessen and Palefsky, {Joel M.} and Giuliano, {Anna R.} and Moreira, {Edson D.} and Eftyhia Vardas and Carlos Aranda and Hillman, {Richard J.} and Ferris, {Daron G.} and Francois Coutlee and Marshall, {J. Brooke} and Scott Vuocolo and Haupt, {Richard M.} and Dalya Guris and Elizabeth Garner",

note = "Funding Information: EM, AG and JP have received research grants from Merck, either personally or through their institution. DGF and AG have received research grants from GlaxoSmithKline . AG, SG, DGF, EV, RJH, JP and EM have received honoraria from Merck for speaking engagements or board membership either personally or through their institutions. SG, DGF, JP and EM have received travel reimbursement from Merck related to scientific meetings. CA has an approved, filed or pending patent related to participant matter discussed in this manuscript. EG, RMH, DG, JBM and SV are employees of Merck and may own Merck stock and/or stock options. ",

year = "2013",

month = aug,

day = "20",

doi = "10.1016/j.vaccine.2013.06.057",

language = "English",

volume = "31",

pages = "3849--3855",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "37",

}

Goldstone, SE, Jessen, H, Palefsky, JM, Giuliano, AR, Moreira, ED, Vardas, E, Aranda, C, Hillman, RJ, Ferris, DG, Coutlee, F, Marshall, JB, Vuocolo, S, Haupt, RM, Guris, D & Garner, E 2013, 'Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males', Vaccine, vol. 31, no. 37, pp. 3849-3855. https://doi.org/10.1016/j.vaccine.2013.06.057

TY - JOUR

T1 - Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

AU - Goldstone, Stephen E.

AU - Jessen, Heiko

AU - Palefsky, Joel M.

AU - Giuliano, Anna R.

AU - Moreira, Edson D.

AU - Vardas, Eftyhia

AU - Aranda, Carlos

AU - Hillman, Richard J.

AU - Ferris, Daron G.

AU - Coutlee, Francois

AU - Marshall, J. Brooke

AU - Vuocolo, Scott

AU - Haupt, Richard M.

AU - Guris, Dalya

AU - Garner, Elizabeth

N1 - Funding Information: EM, AG and JP have received research grants from Merck, either personally or through their institution. DGF and AG have received research grants from GlaxoSmithKline . AG, SG, DGF, EV, RJH, JP and EM have received honoraria from Merck for speaking engagements or board membership either personally or through their institutions. SG, DGF, JP and EM have received travel reimbursement from Merck related to scientific meetings. CA has an approved, filed or pending patent related to participant matter discussed in this manuscript. EG, RMH, DG, JBM and SV are employees of Merck and may own Merck stock and/or stock options.

PY - 2013/8/20

Y1 - 2013/8/20

N2 - A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

AB - A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. This report examines the vaccine's efficacy against disease due to 10 additional non-vaccine HPV types, as well as efficacy regardless of HPV detection. The data presented suggest that vaccinating males against HPV 6, 11, 16 and 18 protects them against most vaccine HPV-type related anogenital disease. However, significant efficacy against disease due to non-vaccine HPV types was not seen. In addition, the data do not provide any evidence that vaccination with qHPV vaccine will increase the likelihood of disease caused by non-vaccine types in the short term.

KW - HPV

KW - Males

KW - Men who have sex with men

KW - Young

UR - http://www.scopus.com/inward/record.url?scp=84881544326&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.06.057

DO - 10.1016/j.vaccine.2013.06.057

M3 - Article

C2 - 23831322

AN - SCOPUS:84881544326

SN - 0264-410X

VL - 31

SP - 3849

EP - 3855

JO - Vaccine

JF - Vaccine

IS - 37

ER -

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males

Abstract

Keywords

Access to Document

Fingerprint

Cite this